Department of Liver Surgery, Liver Transplantation Division, West China Hospital, Sichuan University, Chengdu 610041, China.
Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Aging (Albany NY). 2020 Feb 22;12(4):3451-3472. doi: 10.18632/aging.102821.
Tumor-associated tertiary lymphoid structures (TLS) play a critical role in the progression of various tumors. However, the dynamics of lymphocyte recruitment during hepatocellular carcinoma (HCC) clinical progression have not been fully elucidated. In the present study, tissue microarrays and hematoxylin-eosin staining were used to evaluate the existence and degree of TLS in HCC patients. Nine immune biomarkers in intratumoral tissues were examined by immunohistochemical staining. A total of 462 patients were recruited for the study. Kaplan-Meier analysis showed that TLS was inversely correlated with the risk of early tumor recurrence (P=0.014), whereas no association was found between TLS and overall survival. Cox regression analysis identified TLS as an independent prognostic factor for early HCC recurrence (P=0.005). In addition, TLS was associated with increased intratumoral CD3+, CD8+, CD20+, and decreased infiltration of Foxp3+ and CD68+ cells. A lower density of PD1+, TIM3+, and LAG3+ were found in TLS+ cases. Sub-analysis revealed the prognostic value of TLS on early-stage HCC (BCLC 0-A, TNM stage I-II) and HCC with solitary nodule. The validation cohort verified the prognostic value of TLS in early-stage HCC patients. These results suggest that TLS-targeted immune-modulating therapies may be a potential strategy for effective immune-mediated tumor suppression.
肿瘤相关三级淋巴结构(TLS)在各种肿瘤的进展中起着关键作用。然而,肝癌(HCC)临床进展过程中淋巴细胞募集的动态变化尚未完全阐明。在本研究中,使用组织微阵列和苏木精-伊红染色来评估 HCC 患者中 TLS 的存在和程度。通过免疫组织化学染色检查肿瘤内组织中的 9 种免疫生物标志物。共招募了 462 名患者进行研究。Kaplan-Meier 分析表明,TLS 与早期肿瘤复发的风险呈负相关(P=0.014),而 TLS 与总生存期之间没有关联。Cox 回归分析确定 TLS 是 HCC 早期复发的独立预后因素(P=0.005)。此外,TLS 与肿瘤内 CD3+、CD8+、CD20+细胞的增加以及 Foxp3+和 CD68+细胞浸润的减少相关。在 TLS+病例中发现 PD1+、TIM3+和 LAG3+的密度较低。亚组分析显示 TLS 对早期 HCC(BCLC 0-A、TNM Ⅰ-Ⅱ期)和单发结节 HCC 的预后价值。验证队列验证了 TLS 在早期 HCC 患者中的预后价值。这些结果表明,针对 TLS 的免疫调节治疗可能是一种有效的免疫介导的肿瘤抑制策略。